Payment overview · 2025
General Payments
$4,894.95
208 reported records · 40 companies
Healthcare provider profile · identity verified
Patrick Grogan
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · LACKLAND A F B, TX · NPI 1801815147
Verified facts
What the public records show
CMS Open Payments records show Patrick Grogan received $4,894.95 in general payments during 2025 across 208 reported records.
UCB, Inc. accounted for 11.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 49 associated products.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| UCB, Inc. | Unresolved — no canonical attribution shown | $547.86 | 11.2% | 18 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $434.83 | 8.9% | 20 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $411.86 | 8.4% | 20 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $269.09 | 5.5% | 11 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $252.53 | 5.2% | 18 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $238.14 | 4.9% | 9 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $232.89 | 4.8% | 9 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$211.56 | 4.3% | 9 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $198.06 | 4.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $195.54 | 4.0% | 10 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $191.17 | 3.9% | 7 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$121.28 | 2.5% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $117.30 | 2.4% | 6 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $117.26 | 2.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $108.13 | 2.2% | 6 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $107.79 | 2.2% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $105.28 | 2.1% | 4 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $103.60 | 2.1% | 4 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $100.79 | 2.1% | 1 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $94.84 | 1.9% | 4 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $88.63 | 1.8% | 4 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $76.15 | 1.6% | 4 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $71.08 | 1.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $66.37 | 1.4% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $65.05 | 1.3% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $34.50 | 0.7% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$33.45 | 0.7% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $32.46 | 0.7% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.67 | 0.7% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $28.78 | 0.6% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.68 | 0.6% | 1 | 2025 |
| Dynasplint Systems Inc. | Unresolved — no canonical attribution shown | $26.13 | 0.5% | 1 | 2025 |
| MicroTransponder, Inc. | Unresolved — no canonical attribution shown | $25.30 | 0.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $24.49 | 0.5% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $22.98 | 0.5% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.38 | 0.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.41 | 0.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.34 | 0.3% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.18 | 0.2% | 1 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $12.12 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,894.95 | 208 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $411.86 | 20 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $357.33 | 17 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $318.01 | 14 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $269.09 | 11 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $252.53 | 18 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $230.70 | 8 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $211.56 | 9 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $191.17 | 7 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $183.67 | 6 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $174.88 | 9 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $159.49 | 8 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $158.05 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $151.32 | 8 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $133.49 | 4 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $121.28 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $118.25 | 5 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $117.30 | 6 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $114.64 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $108.13 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $105.28 | 4 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $104.52 | 3 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $103.60 | 4 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $100.79 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc. | $94.84 | 4 | 2025 |
Source payment records
|
|||||
| FIRDAPSE Normalized: firdapse |
Drug | CATALYST PHARMACEUTICALS, INC. | $94.64 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $90.09 | 5 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $84.88 | 3 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $76.15 | 4 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $71.08 | 3 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $53.50 | 2 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $50.49 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $36.05 | 2 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $32.46 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $31.67 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $29.75 | 1 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $26.68 | 1 | 2025 |
Source payment records
|
|||||
| Dynasplint Normalized: dynasplint |
Device | Dynasplint Systems Inc. | $26.13 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $24.49 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $22.98 | 1 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $22.91 | 1 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $22.62 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $20.38 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $12.18 | 1 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $12.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 157 | 53 |
| Pregabalin | Pregabalin | 56 | 15 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 33 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 32 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 15 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,894.95 · 208 records | UCB, Inc. | AJOVY, AMYVID, AUSTEDO XR, Briviact, CREXONT, Dynasplint, EMGALITY, FIRDAPSE, FYCOMPA, Gamunex-C, Gocovri, HYQVIA, Hizentra, INBRIJA, INFINITY, INGREZZA, KEVEYIS, KISUNLA, Leqembi, Motpoly XR, NEURACEQ, NUPLAZID, NURTEC ODT, Nayzilam, ONPATTRO, PANZYGA, PERCEPT PC BRAINSENSE, PONVORY, PROCLAIM, QULIPTA, QUTENZA, Qelbree, REXULTI, Rystiggo, SKYCLARYS, Senza, Sunosi, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, VALTOCO, VUMERITY, VYEPTI, VYVGART, VYVGART HYTRULO, WAINUA, Xeomin, ZAVZPRET | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Takeda Pharmaceuticals U.S.A., Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error